Chairman
PROCTER & GAMBLE Co (PG)Board Member
ELI LILLY & Co (LLY)Equibles does not estimate personal net worth.
Get an email with a short summary when PROCTER & GAMBLE Co publishes a filing, an earnings call transcript or a press release.
Get PG alertsJon Moeller is recorded as Chairman at PROCTER & GAMBLE Co (PG) since January 1, 2026, CEO and CFO at PROCTER & GAMBLE Co (PG) and Board Member at ELI LILLY & Co (LLY) since January 1, 2024. The newest filing on record that lists Jon Moeller as Board Member at ELI LILLY & Co (LLY) is dated March 20, 2026. PROCTER & GAMBLE Co reported in an 8-K filed July 28, 2025 that Jon Moeller was appointed Executive Chairman of the Board, effective January 1, 2026. ELI LILLY & Co reported in an 8-K filed November 19, 2024 that Jon Moeller was appointed new member of the Board, effective December 1, 2024. Jon Moeller has spoken on 16 earnings calls across 1 company, most recently for PROCTER & GAMBLE Co on July 29, 2025. PROCTER & GAMBLE Co is classified in the Household & Personal Products industry within the Consumer Defensive sector. ELI LILLY & Co is classified in the Drug Manufacturers - General industry within the Healthcare sector. Other leadership on record at PROCTER & GAMBLE Co includes Amy L. Chang (CEO and Board Member), Christopher Kempczinski (CEO and Board Member), Debra L. Lee (CEO and Board Member) and 7 others.
“Jon Moeller, Chairman of the Board, President and Chief Executive Officer, will transition into the role of Executive Chairman of the Board, effective January 1, 2026, to serve at the pleasure of the Board of Directors.”
“On November 19, 2024, the Board of Directors (the "Board") of Eli Lilly and Company (the "Company") elected Jon Moeller as a new member of the Board, effective December 1, 2024.”
“I'm going to start the call and then I will hand it over to Andre. Good morning. Obviously, Andre is joining me here, as is John Chevalier, Senior Vice President of Investor Relations.”
“Our team continues to execute our strategy with excellence, enabling strong results over the past six-plus years: pre-COVID, during COVID, through a historic inflationary and pricing cycle, and through geopolitical tensions.”
“I’ll start with a few thoughts on results before discussing the strategy. Our team continues to execute the strategy with excellence, enabling strong results over each of the past six years pre-COVID, during COVID, through a historic inflationary and pricing cycle, and through geopolitical tensions.”
“I'll start by underscoring a few points Andre made in his discussion of the topline trends. Overall, we continue to see strong top line progress, marking the 22nd consecutive quarter of 4% or better organic sales growth, with volume acceleration in key markets and increases in aggregate market shares.”
“I want to talk briefly about this company, its strategy, and our organization both as a step-back reflection on what’s been accomplished and as a glimpse forward to what’s possible.”
2026-01-01–present
2024-01-01–present
Last confirmed March 20, 2026
Household & Personal Products · Consumer Defensive
CEO, CFO, Chairman
2026-01-01–present
LLY
Drug Manufacturers - General · Healthcare
Board Member
2024-01-01–present
